Acadia stock crashed Tuesday after an outsized placebo effect torpedoed the company’s efforts to expand Nuplazid to schizophrenia patients.

The post Acadia Hits 11-Month Low After Outsized Placebo Effect Torpedoes Schizophrenia Study appeared first on Investor’s Business Daily.